Herantis Pharma publishes newsletter for September-October
Herantis Pharma Plc
Press release 4 November 2019 at 9:00 am
Herantis Pharma plc ("Herantis") has published its newsletter for September-October 2019. The newsletter is also attached to this press release.
Herantis' newsletter is published every other month on the company's web site. It is also available by subscription.
Further information:
Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: Herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates, CDNF and Lymfactin, aim to revolutionize the treatment of Parkinson's disease and other neurodegenerative diseases, and of secondary lymphedema. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.
Distribution:
Main media
www.herantis.com
Attachment
- newsletter_oct2019_EN (https://ml-eu.globenewswire.com/Resource/Download/a2277f28-cb88-4cc6-829a-0307573fbeba)
